⚗️ Metabolic Disorder

Homocystinuria

Also known as: Classical Homocystinuria, HCU, CBS Deficiency, Cystathionine Beta-Synthase Deficiency

Homocystinuria is a rare, inherited metabolic disorder caused by a deficiency of cystathionine beta-synthase (CBS), an enzyme essential for processing methionine. This deficiency leads to an abnormal accumulation of homocysteine and its metabolites in the blood and urine, causing a range of systemic complications affecting the eyes, skeleton, brain, and vascular system.

👥 1 in 200,000 to 1 in 300,000 live births Prevalence
🔬 15 Active Trials

Imagine your body has a special machine that helps break down food. In homocystinuria, one part of that machine is broken, causing a build-up of a substance called homocysteine. This can cause problems with your eyes, bones, brain, and blood. Doctors can help by giving you special vitamins and a special diet to keep you healthy.

Signs & Symptoms

  • Dislocation of the lens of the eye (ectopia lentis)
  • Myopia (nearsightedness)
  • Increased risk of blood clots (thromboembolism)
  • Developmental delay
  • Intellectual disability
  • Skeletal abnormalities (e.g., scoliosis, pectus excavatum/carinatum)
  • Osteoporosis
  • Seizures
  • Psychiatric disorders
  • Failure to thrive

Treatment Options

MEDICATION FDA Approved

Vitamin B6 (Pyridoxine) Supplementation

MODERATELY EFFECTIVE
MEDICATION FDA Approved

Betaine (Trimethylglycine)

HIGHLY EFFECTIVE
MEDICATION FDA Approved

Folic Acid Supplementation

SUPPORTIVE
MEDICATION FDA Approved

Vitamin B12 (Cobalamin) Supplementation

SUPPORTIVE
THERAPY

Dietary Methionine Restriction

HIGHLY EFFECTIVE
THERAPY

Cystine Supplementation

SUPPORTIVE
SUPPORTIVE

Management of Thromboembolism

SUPPORTIVE
SURGERY

Ophthalmological Management (e.g., lens extraction)

SUPPORTIVE

Diagnosis

  • Newborn screening (measuring methionine levels)
  • Plasma amino acid analysis (elevated homocysteine and methionine)
  • Urine organic acid analysis (homocysteine metabolites)
  • CBS enzyme activity assay in fibroblasts
  • Genetic testing (CBS gene sequencing)

History

Homocystinuria was first described in 1962 by Gerritsen, Vaughn, and Waisman, who identified elevated levels of homocysteine in the urine of a patient with intellectual disability and dislocated lenses. The enzymatic defect, CBS deficiency, was subsequently identified, leading to a better understanding of the metabolic pathway and the development of targeted therapies.

Recent Breakthroughs

2022

Advances in Newborn Screening for Homocystinuria

Improved tandem mass spectrometry techniques have enhanced the sensitivity and specificity of newborn screening programs, allowing for earlier detection and intervention in infants with homocystinuria.

2023

Novel Therapeutic Approaches Targeting Homocysteine Metabolism

Research is ongoing to explore novel therapeutic strategies, including enzyme replacement therapy and gene therapy, to address the underlying metabolic defect in homocystinuria. Preclinical studies have shown promising results in animal models.